Abstract
Long before the RNA degrading exosome was first described in the yeast Saccharomyces cerevisiae, the use of autoantibodies found in the sera of certain autoimmune patients allowed the identification of a complex of polypeptides which later appeared to be the human exosome. Today, the most extensively documented association of the exosome with disease is still its targeting by the immune system of such patients. The highest frequency of autoantibodies to components of the exosome complex is found in polymyositis-scleroderma overlap patients and therefore the exosome is termed PM/Scl autoantigen in the autoimmune field. More recently, one of the core components of the exosome was identified as a protein associated with chronic myelogenous leukemia. In this chapter we will describe the identification of the PM/Scl autoantigen from a historical perspective, discuss our current knowledge on the occurrence of autoantibodies to exosome components in autoimmune diseases and end with the data that connect the exosome with cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
van Dijk EL, Schilders G, Pruijn GJ. Human cell growth requires a functional cytoplasmic exosome, which is involved in various mRNA decay pathways. RNA 2007; 13:1027–1035.
Allmang C, Petfalski E, Podtelejnikov A et al. The yeast exosome and human PM-Scl are related complexes of 3′→5′ exonucleases. Genes Dev 1999; 13:2148–2158.
Mitchell P, Petfalski E, Shevchenko A et al. The exosome: a conserved eukaryotic RNA processing complex containing multiple 3′→5′ exoribonucleases. Cell 1997; 91:457–466.
Wolfe JF, Adelstein E, Sharp GC. Antinuclear antibody with distinct specificity for polymyositis. J Clin Invest 1977; 59:176–178.
Treadwell EL, Alspaugh MA, Wolfe JF et al. Clinical relevance of PM-1 antibody and physiochemical characterization of PM-1 antigen. J Rheumatol 1984; 11:658–662.
Reichlin M, Maddison PJ, Targoff I et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984; 4:40–44.
Reimer G, Scheer U, Peters JM et al. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes. J Immunol 1986; 137:3802–3808.
Alderuccio F, Chan EK, Tan EM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/ scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J Exp Med 1991; 173:941–952.
Bluthner M, Bautz FA. Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndrome-related nucleolar 100-kD protein. J Exp Med 1992; 176:973–980.
Ge Q, Frank MB, O’Brien C et al. Cloning of a complementary DNA coding for the 100-kD antigenic protein of the PM-Scl autoantigen. J Clin Invest 1992; 90:559–570.
Raijmakers R, Vree Egberts WT, van Venrooij WJ et al. The association of the human PM/Scl-75 autoantigen with the exosome is dependent on a newly identified N terminus. J Biol Chem 2003; 278:30698–30704.
Raijmakers R, Vree Egberts WT, van Venrooij WJ et al. Protein-protein interactions between human exosome components support the assembly of RNase PH-type subunits into a six-membered PNPase-like ring. J Mol Biol 2002; 323:653–663.
Brouwer R, Allmang C, Raijmakers R et al. Three novel components of the human exosome. J Biol Chem 2001; 276:6177–6184.
Chen CY, Gherzi R, Ong SE et al. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 2001; 107:451–464.
von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995; 24:323–358.
Reimer G, Steen VD, Penning CA et al. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988; 31:525–532.
Lehner B, Sanderson CM. A protein interaction framework for human mRNA degradation. Genome Res 2004; 14:1315–1323.
Schilders G, Raijmakers R, Raats JM et al. MPP6 is an exosome-associated RNA-binding protein involved in 5.8S rRNA maturation. Nucleic Acids Res 2005; 33:6795–6804.
Schilders G, van Dijk EL, Pruijn GJ. C1D and hMtr4p associate with the human exosome subunit PM/ Scl-100 and are involved in prerRNA processing. Nucleic Acids Res 2007; 35:2564–2572.
Schilders G, Vree Egberts WT, Raijmakers R et al. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome. Arthritis Rheum 2007; 56:2449–2454.
Brouwer R, Vree Egberts WT, Hengstman GJ et al. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002; 4:134–138.
Raijmakers R, Renz M, Wiemann C et al. PM-Scl-75 is the main autoantigen inpatients with the polymyositis/ scleroderma overlap syndrome. Arthritis Rheum 2004; 50:565–569.
Bluthner M, Mahler M, Muller DB et al. Identification of an alpha-helical epitope region on the PM/ Scl-100 autoantigen with structural homology to a region on the heterochromatin p25beta autoantigen using immobilized overlapping synthetic peptides. J Mol Med 2000; 78:47–54.
Mahler M, Raijmakers R, Dahnrich C et al. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther 2005; 7:R704–R713.
Kuwana M, Okano Y, Kaburaki J et al. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994; 37:902–906.
Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW et al. Clinical, sérologic and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40:1257–1266.
Chinoy H, Salway F, Fertig N et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8:R13.
O’Hanlon TP, Carrick DM, Targoff IN et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A,-B,-Cw,-DRB1 and-DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006; 85:111–127.
Utz PJ, Gensler TJ, Anderson P. Death, autoantigen modifications and tolerance. Arthritis Res 2000; 2:101–114.
Hof D, Pruijn GJM, van Venrooij WJ et al. The role of cell death-specific modifications in breaking tolerance to self-antigens. In: Kettleworth CR, ed. Cell Apoptosis Research Advances. Hauppauge: Nova Science Publishers, 2007:179–202.
Schilders G, Raijmakers R, Malmegrim KC et al. Caspase-mediated cleavage of the exosome subunit PM/ Scl-75 during apoptosis. Arthritis Res Ther 2007; 9:R12.
Casciola-Rosen L, Andrade F, Ulanet D et al. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999; 190:815–826.
Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007; 6:432–437.
Gutierrez-Ramos R, Gonz Lez-Diaz V, Pacheco Tovar MG et al. A dermatomyositis and scleroderma overlap syndrome with a remarkable high titer of anti-exosome antibodies. Reumatismo 2008; 60:296–300.
Yang XF, Wu CJ, Chen L et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res 2002; 62:5517–5522.
Faderl S, Talpaz M, Estrov Z et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131:207–219.
Collins RH, Jr., Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433–444.
Wu CJ, Yang XF, McLaughlin S et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000; 106:705–714.
Zhou H, Zhang D, Wang Y et al. Induction of CML28-specific cytotoxic T-cell responses using cotransfected dendritic cells with CML28 DNA vaccine and SOCS1 small interfering RNA expression vector. Biochem Biophys Res Commun 2006; 347:200–207.
Xie LH, Sin FW, Cheng SC et al. Activation of cytotoxic T lymphocytes against CML28-bearing tumors by dendritic cells transduced with a recombinant adeno-associated virus encoding the CML28 gene. Cancer Immunol Immunother 2008; 57:1029–1038.
Mao H, Geng Z, Liu W et al. Selection of HLA-A2 restricted CML28 peptide by artificial antigen-presenting cells. J Immunother 2008; 31:487–490.
Fang F, Hoskins J, Butler JS. 5-fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs. Mol Cell Biol 2004; 24:10766–10776.
Lum PY, Armour CD, Stepaniants SB et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 2004; 116:121–137.
Khabar KS. The AU-rich transcriptome: more than interferons and cytokines and its role in disease. J Interferon Cytokine Res 2005; 25: 1–10.
Xi L, Moscou MJ, Meng Y et al. Transcript-based cloning of RRP46, a regulator of rRNA processing and R gene-independent cell death in barley-powdery mildew interactions. Plant Cell 2009; 21:3280–3295.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Staals, R.H.J., Pruijn, G.J.M. (2010). The Human Exosome and Disease. In: Jensen, T.H. (eds) RNA Exosome. Advances in Experimental Medicine and Biology, vol 702. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7841-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7841-7_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-7840-0
Online ISBN: 978-1-4419-7841-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)